NASDAQ: BIIB |
| Healthcare / Drug Manufacturers / USA |
195.52 | -7.38 | -3.64% | Vol 823.14K | 1Y Perf -27.80% |
May 18th, 2022 15:51 DELAYED |
BID | 195.51 | ASK | 195.59 | ||
Open | 201.05 | Previous Close | 202.90 | ||
Pre-Market | 198.26 | After-Market | - | ||
-4.64 -2.29% | - - |
Target Price | 271.18 | Analyst Rating | Moderate Buy 2.09 | |
Potential % | 38.55 | Finscreener Ranking | ★+ 43.09 | |
Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★+ 49.04 | |
Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★ 51.89 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 2.97 | Earnings Rating | Sell | |
Market Cap | 28.63B | Earnings Date | 3rd May 2022 | |
Alpha | -0.00 | Standard Deviation | 0.10 | |
Beta | 0.42 |
Today's Price Range 195.46201.77 | 52W Range 187.16468.55 | 5 Year PE Ratio Range 7.1032.60 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 6.19% | ||
1 Month | -4.54% | ||
3 Months | -3.28% | ||
6 Months | -20.99% | ||
1 Year | -27.80% | ||
3 Years | -11.51% | ||
5 Years | -19.74% | ||
10 Years | 54.20% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 18.64 | |||
ROE last 12 Months | 13.59 | |||
ROA (5Y Avg) | 9.50 | |||
ROA last 12 Months | 6.28 | |||
ROC (5Y Avg) | 18.52 | |||
ROC last 12 Months | 8.77 | |||
Return on invested Capital Q | 1.84 | |||
Return on invested Capital Y | 2.27 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 5.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
20.40 | ||||
2.59 | ||||
2.69 | ||||
9.70 | ||||
10.50 | ||||
20.43 | ||||
8.75 | ||||
76.76 | ||||
33.00B | ||||
Forward PE | 12.11 | |||
PEG | 1.96 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.50 | ||||
2.00 | ||||
0.37 | ||||
0.67 | ||||
7.60 | ||||
Leverage Ratio | 2.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
77.00 | ||||
17.40 | ||||
25.20 | ||||
37.50 | ||||
14.08 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
10.82B | ||||
73.88 | ||||
-7.70 | ||||
-0.75 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | 4.41 | 3.62 | -17.91 |
Q04 2021 | 3.32 | 3.39 | 2.11 |
Q03 2021 | 4.15 | 4.77 | 14.94 |
Q02 2021 | 4.57 | 5.68 | 24.29 |
Q01 2021 | 5.06 | 5.34 | 5.53 |
Q04 2020 | 4.93 | 4.58 | -7.10 |
Q03 2020 | 8.06 | 8.84 | 9.68 |
Q02 2020 | 8.03 | 10.26 | 27.77 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 4.11 | -1.67 | Negative |
9/2022 QR | 3.93 | 4.24 | Positive |
12/2022 FY | 15.43 | 0.33 | Positive |
12/2023 FY | 16.44 | 0.00 | - |
Next Report Date | - |
Estimated EPS Next Report | 4.41 |
Estimates Count | 29 |
EPS Growth Next 5 Years % | 10.40 |
Volume Overview | |
---|---|
Volume | 823.14K |
Shares Outstanding | 146.45K |
Shares Float | 129.76M |
Trades Count | 20.30K |
Dollar Volume | 162.97M |
Avg. Volume | 1.02M |
Avg. Weekly Volume | 907.85K |
Avg. Monthly Volume | 1.10M |
Avg. Quarterly Volume | 1.06M |
Biogen Inc. (NASDAQ: BIIB) stock closed at 202.9 per share at the end of the most recent trading day (a 2.28% change compared to the prior day closing price) with a volume of 628.11K shares and market capitalization of 28.63B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9100 people. Biogen Inc. CEO is Michel Vounatsos.
The one-year performance of Biogen Inc. stock is -27.8%, while year-to-date (YTD) performance is -15.43%. BIIB stock has a five-year performance of -19.74%. Its 52-week range is between 187.16 and 468.55, which gives BIIB stock a 52-week price range ratio of 2.97%
Biogen Inc. currently has a PE ratio of 20.40, a price-to-book (PB) ratio of 2.59, a price-to-sale (PS) ratio of 2.69, a price to cashflow ratio of 9.70, a PEG ratio of 2.32, a ROA of 6.28%, a ROC of 8.77% and a ROE of 13.59%. The company’s profit margin is 14.08%, its EBITDA margin is 25.20%, and its revenue ttm is $10.82 Billion , which makes it $73.88 revenue per share.
Of the last four earnings reports from Biogen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $4.41 for the next earnings report. Biogen Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Biogen Inc. is Moderate Buy (2.09), with a target price of $271.18, which is +38.55% compared to the current price. The earnings rating for Biogen Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biogen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biogen Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.35, ATR14 : 6.96, CCI20 : -30.96, Chaikin Money Flow : -0.24, MACD : -3.69, Money Flow Index : 43.65, ROC : -2.19, RSI : 49.13, STOCH (14,3) : 57.00, STOCH RSI : 1.00, UO : 51.32, Williams %R : -43.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biogen Inc. in the last 12-months were: Alfred W. Sandrock (Sold 15 344 shares of value $6 751 360 ), Brian S. Posner (Sold 720 shares of value $197 402 ), Chirfi Guindo (Option Excercise at a value of $0), Chirfi Guindo (Sold 6 174 shares of value $2 716 560 ), Ginger Gregory (Option Excercise at a value of $0), Michael R. Mcdonnell (Option Excercise at a value of $2 031 130), Michel Vounatsos (Option Excercise at a value of $0), Nicole Murphy (Option Excercise at a value of $0), Rachid Izzar (Option Excercise at a value of $85 009), Robin C. Kramer (Option Excercise at a value of $175 158), Susan H. Alexander (Option Excercise at a value of $0)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
CEO: Michel Vounatsos
Telephone: +1 617 679-2000
Address: 225 Binney Street, Cambridge 02142, MA, US
Number of employees: 9 100
Thu, 12 May 2022 16:38 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB) and Altimmune (ALT)
- TipRanks. All rights reserved.Wed, 04 May 2022 10:26 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Veracyte (VCYT) and Kala Pharmaceuticals (KALA)
- TipRanks. All rights reserved.Sat, 30 Apr 2022 03:54 GMT Biogen (BIIB) Receives a Hold from Robert W. Baird
- TipRanks. All rights reserved.Sat, 09 Apr 2022 03:15 GMT Biogen (BIIB) Receives a Buy from Leerink Partners
- TipRanks. All rights reserved.Fri, 08 Apr 2022 16:14 GMT Biogen Wavers as Aduhelm Support Wanes
- TipRanks. All rights reserved.Wed, 06 Apr 2022 01:55 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Pacira Pharmaceuticals (PCRX)
- TipRanks. All rights reserved.Mon, 21 Mar 2022 15:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Knight Therapeutics (OtherKHTRF) and Mersana Therapeutics (MRSN)
- TipRanks. All rights reserved.Mon, 21 Feb 2022 18:32 GMT Biogen: Alzheimers Treatment Could Be a Great Success
- TipRanks. All rights reserved.Sat, 12 Feb 2022 09:06 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Becton Dickinson (BDX), Biogen (BIIB) and AmerisourceBergen (ABC)
- TipRanks. All rights reserved.Fri, 04 Feb 2022 09:24 GMT Biogen Delivers Mixed Q4 Results Shares Hit All-Time Low
- TipRanks. All rights reserved.Thu, 03 Feb 2022 16:55 GMT Biogen Slips as Drug Sales Prove Tepid
- TipRanks. All rights reserved.Thu, 03 Feb 2022 13:25 GMT Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Adicet Bio (ACET)
- TipRanks. All rights reserved.Fri, 21 Jan 2022 15:47 GMT Biogen: Promising Pipeline, Needs Catalysts as Profitability Weakens
- TipRanks. All rights reserved.Fri, 21 Jan 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), UnitedHealth (UNH) and Molecular Partners AG (OtherMLLCF)
- TipRanks. All rights reserved.Thu, 20 Jan 2022 17:36 GMT Biogen: Alzheimers Treatment Has a Bad Start
- TipRanks. All rights reserved.Fri, 14 Jan 2022 13:05 GMT Analysts Top Healthcare Picks: Biogen (BIIB), Zoetis (ZTS)
- TipRanks. All rights reserved.Thu, 13 Jan 2022 06:55 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Masimo (MASI) and Beyondspring (BYSI)
- TipRanks. All rights reserved.Thu, 13 Jan 2022 06:45 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Incyte (INCY) and InflaRx (IFRX)
- TipRanks. All rights reserved.Tue, 11 Jan 2022 11:55 GMT Biogen (BIIB) Received its Third Buy in a Row
- TipRanks. All rights reserved.Thu, 06 Jan 2022 16:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Pacira Pharmaceuticals (PCRX)
- TipRanks. All rights reserved.Sun, 02 Jan 2022 09:27 GMT Biogen Blasts Up, Plunges on Samsung Rumors
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.